DOCSLIB.ORG

Ehealth DSI [Ehdsi V2.2.1] European Commission

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ehealth DSI [Ehdsi V2.2.1] European Commission MTC eHealth DSI [eHDSI v2.2.1] European Commission - Master Translation/Transcoding Catalogue Responsible : eHDSI Solution Provider PublishDate : Thu Jun 01 17:03:48 CEST 2017 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 A01 STOMATOLOGICAL PREPARATIONS 2.16.840.1.113883.6.73 2017-01 A01A STOMATOLOGICAL PREPARATIONS 2.16.840.1.113883.6.73 2017-01 A01AA Caries prophylactic agents 2.16.840.1.113883.6.73 2017-01 A01AA01 sodium fluoride 2.16.840.1.113883.6.73 2017-01 A01AA02 sodium monofluorophosphate 2.16.840.1.113883.6.73 2017-01 A01AA03 olaflur 2.16.840.1.113883.6.73 2017-01 A01AA04 stannous fluoride 2.16.840.1.113883.6.73 2017-01 A01AA30 combinations 2.16.840.1.113883.6.73 2017-01 A01AA51 sodium fluoride, combinations 2.16.840.1.113883.6.73 2017-01 A01AB Antiinfectives and antiseptics for local oral treatment 2.16.840.1.113883.6.73 2017-01 A01AB02 hydrogen peroxide 2.16.840.1.113883.6.73 2017-01 A01AB03 chlorhexidine 2.16.840.1.113883.6.73 2017-01 A01AB04 amphotericin B 2.16.840.1.113883.6.73 2017-01 A01AB05 polynoxylin 2.16.840.1.113883.6.73 2017-01 A01AB06 domiphen 2.16.840.1.113883.6.73 2017-01 A01AB07 oxyquinoline 2.16.840.1.113883.6.73 2017-01 A01AB08 neomycin 2.16.840.1.113883.6.73 2017-01 A01AB09 miconazole 2.16.840.1.113883.6.73 2017-01 A01AB10 natamycin 2.16.840.1.113883.6.73 2017-01 A01AB11 various 2.16.840.1.113883.6.73 2017-01 A01AB12 hexetidine 2.16.840.1.113883.6.73 2017-01 A01AB13 tetracycline 2.16.840.1.113883.6.73 2017-01 A01AB14 benzoxonium chloride 2.16.840.1.113883.6.73 2017-01 A01AB15 tibezonium iodide 2.16.840.1.113883.6.73 2017-01 A01AB16 mepartricin 2.16.840.1.113883.6.73 2017-01 A01AB17 metronidazole 2.16.840.1.113883.6.73 2017-01 A01AB18 clotrimazole 2.16.840.1.113883.6.73 2017-01 A01AB19 sodium perborate 2.16.840.1.113883.6.73 2017-01 A01AB21 chlortetracycline 2.16.840.1.113883.6.73 2017-01 A01AB22 doxycycline 2.16.840.1.113883.6.73 2017-01 A01AB23 minocycline © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 4 of 490 MTC epSOSActiveIngredient 2.16.840.1.113883.6.73 2017-01 A01AC Corticosteroids for local oral treatment 2.16.840.1.113883.6.73 2017-01 A01AC01 triamcinolone 2.16.840.1.113883.6.73 2017-01 A01AC02 dexamethasone 2.16.840.1.113883.6.73 2017-01 A01AC03 hydrocortisone 2.16.840.1.113883.6.73 2017-01 A01AC54 prednisolone, combinations 2.16.840.1.113883.6.73 2017-01 A01AD Other agents for local oral treatment 2.16.840.1.113883.6.73 2017-01 A01AD01 epinephrine 2.16.840.1.113883.6.73 2017-01 A01AD02 benzydamine 2.16.840.1.113883.6.73 2017-01 A01AD05 acetylsalicylic acid 2.16.840.1.113883.6.73 2017-01 A01AD06 adrenalone 2.16.840.1.113883.6.73 2017-01 A01AD07 amlexanox 2.16.840.1.113883.6.73 2017-01 A01AD08 becaplermin 2.16.840.1.113883.6.73 2017-01 A01AD11 various 2.16.840.1.113883.6.73 2017-01 A02 DRUGS FOR ACID RELATED DISORDERS 2.16.840.1.113883.6.73 2017-01 A02A ANTACIDS 2.16.840.1.113883.6.73 2017-01 A02AA Magnesium compounds 2.16.840.1.113883.6.73 2017-01 A02AA01 magnesium carbonate 2.16.840.1.113883.6.73 2017-01 A02AA02 magnesium oxide 2.16.840.1.113883.6.73 2017-01 A02AA03 magnesium peroxide 2.16.840.1.113883.6.73 2017-01 A02AA04 magnesium hydroxide 2.16.840.1.113883.6.73 2017-01 A02AA05 magnesium silicate 2.16.840.1.113883.6.73 2017-01 A02AA10 combinations 2.16.840.1.113883.6.73 2017-01 A02AB Aluminium compounds 2.16.840.1.113883.6.73 2017-01 A02AB01 aluminium hydroxide 2.16.840.1.113883.6.73 2017-01 A02AB02 algeldrate 2.16.840.1.113883.6.73 2017-01 A02AB03 aluminium phosphate 2.16.840.1.113883.6.73 2017-01 A02AB04 dihydroxialumini sodium carbonate 2.16.840.1.113883.6.73 2017-01 A02AB05 aluminium acetoacetate 2.16.840.1.113883.6.73 2017-01 A02AB06 aloglutamol 2.16.840.1.113883.6.73 2017-01 A02AB07 aluminium glycinate 2.16.840.1.113883.6.73 2017-01 A02AB10 combinations 2.16.840.1.113883.6.73 2017-01 A02AC Calcium compounds 2.16.840.1.113883.6.73 2017-01 A02AC01 calcium carbonate 2.16.840.1.113883.6.73 2017-01 A02AC02 calcium silicate 2.16.840.1.113883.6.73 2017-01 A02AC10 combinations 2.16.840.1.113883.6.73 2017-01 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 2.16.840.1.113883.6.73 2017-01 A02AD01 ordinary salt combinations 2.16.840.1.113883.6.73 2017-01 A02AD02 magaldrate 2.16.840.1.113883.6.73 2017-01 A02AD03 almagate 2.16.840.1.113883.6.73 2017-01 A02AD04 hydrotalcite 2.16.840.1.113883.6.73 2017-01 A02AD05 almasilate 2.16.840.1.113883.6.73 2017-01 A02AF Antacids with antiflatulents © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 5 of 490 MTC epSOSActiveIngredient 2.16.840.1.113883.6.73 2017-01 A02AF01 magaldrate and antiflatulents 2.16.840.1.113883.6.73 2017-01 A02AF02 ordinary salt combinations and antiflatulents 2.16.840.1.113883.6.73 2017-01 A02AG Antacids with antispasmodics 2.16.840.1.113883.6.73 2017-01 A02AH Antacids with sodium bicarbonate 2.16.840.1.113883.6.73 2017-01 A02AX Antacids, other combinations 2.16.840.1.113883.6.73 2017-01 A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) 2.16.840.1.113883.6.73 2017-01 A02BA H2-receptor antagonists 2.16.840.1.113883.6.73 2017-01 A02BA01 cimetidine 2.16.840.1.113883.6.73 2017-01 A02BA02 ranitidine 2.16.840.1.113883.6.73 2017-01 A02BA03 famotidine 2.16.840.1.113883.6.73 2017-01 A02BA04 nizatidine 2.16.840.1.113883.6.73 2017-01 A02BA05 niperotidine 2.16.840.1.113883.6.73 2017-01 A02BA06 roxatidine 2.16.840.1.113883.6.73 2017-01 A02BA07 ranitidine bismuth citrate 2.16.840.1.113883.6.73 2017-01 A02BA08 lafutidine 2.16.840.1.113883.6.73 2017-01 A02BA51 cimetidine, combinations 2.16.840.1.113883.6.73 2017-01 A02BA53 famotidine, combinations 2.16.840.1.113883.6.73 2017-01 A02BB Prostaglandins 2.16.840.1.113883.6.73 2017-01 A02BB01 misoprostol 2.16.840.1.113883.6.73 2017-01 A02BB02 enprostil 2.16.840.1.113883.6.73 2017-01 A02BC Proton pump inhibitors 2.16.840.1.113883.6.73 2017-01 A02BC01 omeprazole 2.16.840.1.113883.6.73 2017-01 A02BC02 pantoprazole 2.16.840.1.113883.6.73 2017-01 A02BC03 lansoprazole 2.16.840.1.113883.6.73 2017-01 A02BC04 rabeprazole 2.16.840.1.113883.6.73 2017-01 A02BC05 esomeprazole 2.16.840.1.113883.6.73 2017-01 A02BC06 dexlansoprazole 2.16.840.1.113883.6.73 2017-01 A02BC07 dexrabeprazole 2.16.840.1.113883.6.73 2017-01 A02BC53 lansoprazole, combinations 2.16.840.1.113883.6.73 2017-01 A02BC54 rabeprazole, combinations 2.16.840.1.113883.6.73 2017-01 A02BD Combinations for eradication of Helicobacter pylori 2.16.840.1.113883.6.73 2017-01 A02BD01 omeprazole, amoxicillin and metronidazole 2.16.840.1.113883.6.73 2017-01 A02BD02 lansoprazole, tetracycline and metronidazole 2.16.840.1.113883.6.73 2017-01 A02BD03 lansoprazole, amoxicillin and metronidazole 2.16.840.1.113883.6.73 2017-01 A02BD04 pantoprazole, amoxicillin and clarithromycin 2.16.840.1.113883.6.73 2017-01 A02BD05 omeprazole, amoxicillin and clarithromycin 2.16.840.1.113883.6.73 2017-01 A02BD06 esomeprazole, amoxicillin and clarithromycin 2.16.840.1.113883.6.73 2017-01 A02BD07 lansoprazole, amoxicillin and clarithromycin 2.16.840.1.113883.6.73 2017-01 A02BD08 bismuth subcitrate, tetracycline and metronidazole 2.16.840.1.113883.6.73 2017-01 A02BD09 lansoprazole, clarithromycin and tinidazole 2.16.840.1.113883.6.73 2017-01 A02BD10 lansoprazole, amoxicillin and levofloxacin 2.16.840.1.113883.6.73 2017-01 A02BD11 pantoprazole, amoxicillin, clarithromycin and metronidazole © eHealth DSI eHDSI Solution Provider v2.2.1 Thu Jun 01 17:03:48 CEST 2017 Page 6 of 490 MTC epSOSActiveIngredient 2.16.840.1.113883.6.73 2017-01 A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 2.16.840.1.113883.6.73 2017-01 A02BX01 carbenoxolone 2.16.840.1.113883.6.73 2017-01 A02BX02 sucralfate 2.16.840.1.113883.6.73 2017-01 A02BX03 pirenzepine 2.16.840.1.113883.6.73 2017-01 A02BX04 methiosulfonium chloride 2.16.840.1.113883.6.73 2017-01 A02BX05 bismuth subcitrate 2.16.840.1.113883.6.73 2017-01 A02BX06 proglumide 2.16.840.1.113883.6.73 2017-01 A02BX07 gefarnate 2.16.840.1.113883.6.73 2017-01 A02BX08 sulglicotide 2.16.840.1.113883.6.73 2017-01 A02BX09 acetoxolone 2.16.840.1.113883.6.73 2017-01 A02BX10 zolimidine 2.16.840.1.113883.6.73 2017-01 A02BX11 troxipide 2.16.840.1.113883.6.73 2017-01 A02BX12 bismuth subnitrate 2.16.840.1.113883.6.73 2017-01 A02BX13 alginic acid 2.16.840.1.113883.6.73 2017-01 A02BX51 carbenoxolone, combinations excl.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
    USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
    [Show full text]
  • Cross-Linking of Alpha 2-Plasmin Inhibitor to Fibrin by Fibrin- Stabilizing Factor
    Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin- stabilizing factor. Y Sakata, N Aoki J Clin Invest. 1980;65(2):290-297. https://doi.org/10.1172/JCI109671. Research Article The concentration of alpha 2-plasmin inhibitor in blood plasma is higher than that in serum obtained from the blood clotted in the presence of calcium ions, but is the same as that in serum obtained in the absence of calcium ions. Radiolabeled alpha2-plasmin inhibitor was covalently bound to fibrin only when calcium ions were present at the time of clotting of plasma or fibrinogen. Whereas, when batroxobin, a snake venom enzyme that lacks the ability to activate fibrin- stabilizing factor, was used for clotting fibrinogen, the binding was not observed. When fibrin-stablizing, factor-deficient plasma was clotted, the specific binding of alpha 2-plasmin inhibitor to fibrin did not occur even in the presence of calcium ions and the concentration of alpha 2-plasmin inhibitor in serum was the same as that in plasma. Monodansyl cadaverine, a fluorescent substrate of the fibrin-stablizing factor, was incorporated into alpha 2-plasmin inhibitor by activated fibrin-stablizing factor. All these findings indicate that alpha 2-plasmin inhibitor is cross-linked to fibrin by activated fibrin-stabilizing factor when blood is clotted. Analysis of alpha 2-plasmin inhibitor-incorporated fibrin by sodium dodecyl sulfate gel electrophoresis showed that the inhibitor was mainly cross-linked to polymerized alpha-chains of cross-linked fibrin. Cross-linking of alpha 2-plasmin inhibitor to fibrin renders fibrin clot less susceptible to fibrinolysis by plasmin.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]